 |
|
 |
 |
 |
Pharmacokinetics
- LESCOL® XL has a patent protected extended-release formulation1,2
- The pharmacokinetic profile of LESCOL® XL results in very little systemic exposure
Pharmacokinetic data in healthy volunteers show that LESCOL® XL:
- Is slowly released over 8 hours, following oral administration1
- Reaches peak concentration within 2.5 to 3 hours post-dose*,3
- Has a mean relative bioavailabilty of 29%, compared with immediate-release capsule, under fasting conditions3
|
*3 hours under fasting conditions, after a low-fat meal, or 2.5 hours after a low-fat meal.
|
References:
1. Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol. 2001:37:502-511.
2. Data on file. XU032OB Study W251. Novartis Pharmaceuticals Corporation.
3. LESCOL® XL full Prescribing Information.
|
|
|
| |
|
|
|
| |
 |
|
|
